Seeking Alpha
 

Celsion Corporation (CLSN)

- NASDAQ
  • Fri, Feb. 20, 9:29 AM
    • Thinly-traded nano cap Celsion (NASDAQ:CLSN) is up 12% premarket on increased volume in response to its update on its advancement of GEN-1, its DNA-based immunotherapy, for the front-line treatment of advanced platinum-resistant and recurring ovarian cancer.
    • The FDA has cleared the Phase 1 dose escalation trial of GEN-1 in combination with the standard of care in neo-adjuvant ovarian cancer. The trial should commence at five to six U.S. medical centers by mid-year.
    • The company presents clinical and preclinical data showing the safety, biological activity and clinical benefits of GEN-1 today at the Molecular Medicine TRI-Conference in San Francisco. In an earlier Phase 1 study, GEN-1 demonstrated a disease control rate (DCR) of 31% and median overall survival (OS) of 18 months. In a Phase 2 study, it demonstrated a DCR of 45% and median OS of 10 months. DCR is the proportion of patients who show a response to treatment.
    | Comment!
  • Fri, Feb. 20, 9:16 AM
    | Comment!
  • Nov. 12, 2014, 12:18 PM
    • Celsion Corp. (CLSN +2%) Q3 results: Revenues: $0.13M (unch); R&D Expense: $4.6M (+100.0%); G&A: $2M (+42.9%); Operating Loss: ($6.7M) (-91.4%); Net Loss: ($6.9M) (-68.3%); Loss Per Share: ($0.35) (-16.7%); Quick Assets: $43.8M (+1.6%).
    • No guidance given.
    | Comment!
  • Nov. 11, 2014, 12:58 PM
    • Celsion (NASDAQ:CLSN): Q3 EPS of -$0.35 misses by $0.03.
    • Revenue of $0.13M in-line (flat Y/Y).
    • Press Release
    | Comment!
  • Nov. 4, 2014, 11:50 AM
    • Celsion (CLSN -3%) will report Q3 results on November 11 after the close. The conference call will begin at 4:30 pm ET.
    • Consensus view is a loss of ($0.32) per share on revenues of $150K.
    | Comment!
  • Aug. 7, 2014, 10:48 AM
    • Celsion Corp. (CLSN +3.1%) Q2 results: Revenue: $125K (unch); Operating Expenses: $6.5M (+64.6%); Operating Loss: ($6.4M) (-66.7%); Net Loss: ($6.7M) (-999%); Loss Per Share: ($0.38) (-999%); Quick Assets: $50.1M (+16.2%).
    • No guidance given.
    | Comment!
  • Aug. 7, 2014, 8:14 AM
    • Celsion (NASDAQ:CLSN): Q2 EPS of -$0.38 may not be comparable to consensus of -$0.32.
    • Revenue of $0.13M (flat Y/Y) in-line.
    • Press Release
    | Comment!
  • Jul. 28, 2014, 9:12 AM
    | Comment!
  • Jul. 24, 2014, 9:18 AM
    | 2 Comments
  • Jul. 24, 2014, 8:56 AM
    • Stoked by investors' ravenous response to Puma Biotechnology's success with neratinib, shares of Celsion (NASDAQ:CLSN) are up 15% premarket on good volume in response to its announcement of positive interim data from its Phase 2 clinical trial evaluating Thermodox in recurrent chest wall breast cancer. Of the 13 patients enrolled to date, 10 were eligible for evaluating efficacy. Six of the 10 patients experienced a stabilization of their highly refractory disease with a local response rate of 50% observed in all 10 patients. Three subjects had complete responses, two had partial responses and one had stable disease.
    • CLSN shares are down ~93% from their January 2013 highs.
    | Comment!
  • Jun. 10, 2014, 9:13 AM
    | Comment!
  • Jun. 10, 2014, 8:19 AM
    • Celsion (CLSN) acquires privately-held biopharmaceutical firm EGEN for $14M in cash and stock. EGEN focuses on the development of nucleic acid-based therapeutics for cancer and other difficult-to-treat diseases.
    • Under the terms of the acquisition agreement, Celsion will make an upfront payment of $10.6M in CLSN common stock and $3.4M in cash. $2.1M in stock will be held back for 24 months for expense adjustments and indemnification claims.
    • Celsion will owe an additional $30.4M to EGEN based on the successful completion of certain development and licensing milestones.
    | Comment!
  • May. 21, 2014, 8:47 AM
    • Celsion (CLSN) receives regulatory clearance to start a Phase III study of its ThermoDox treatment for primary liver cancer in Taiwan, Hong Kong, South Korea and Canada.
    • The company has also applied for approval to conduct trials in the Philippines, Thailand, China and Europe
    • Celsion has already received FDA clearance for the study, whose primary endpoint is overall survival.
    • The company expects to enroll 550 patients globally at up to 100 sites. (PR)
    | Comment!
  • May. 8, 2014, 9:57 AM
    • Celsion (CLSN): Q1 EPS of -$0.33 misses by $0.09.
    • Revenue of $0.13M (flat% Y/Y) in line.
    • Press Release
    | Comment!
  • Feb. 24, 2014, 9:54 AM
    • The FDA has cleared Celesion's (CLSN +6.35%) Optima Phase III trial of its ThermoDox therapy for treating hepatocellular carcinoma (HCC), the most common type of liver cancer.
    • In a previous late-stage study, called Heat, ThermoDox failed in its primary goal of progression-free survival. However, ThermoDox did improve overall survival rates by 55% in a substantial number of HCC patients.
    • Celsion expects to launch the new study in the first half of 2014; the primary endpoint is overall survival. (PR)
    | Comment!
  • Feb. 24, 2014, 9:11 AM
    | Comment!
Visit Seeking Alpha's
CLSN vs. ETF Alternatives
Company Description
Celsion Corp is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer.
Sector: Healthcare
Industry: Biotechnology
Country: United States